<DOC>
	<DOC>NCT01604395</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).</brief_summary>
	<brief_title>Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA and ISS in Children</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>short stature children aged 2 years or more children with GHD,TS, CRF, SGA or ISS written informed consent from the person, person's parent or legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>GHD</keyword>
	<keyword>TS</keyword>
	<keyword>CRF</keyword>
	<keyword>SGA</keyword>
	<keyword>ISS</keyword>
</DOC>